289 related articles for article (PubMed ID: 23810013)
1. ADAM22 as a prognostic and therapeutic drug target in the treatment of endocrine-resistant breast cancer.
Bolger JC; Young LS
Vitam Horm; 2013; 93():307-21. PubMed ID: 23810013
[TBL] [Abstract][Full Text] [Related]
2. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
Li J; Lu M; Jin J; Lu X; Xu T; Jin S
Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
[TBL] [Abstract][Full Text] [Related]
3. Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer.
McCartan D; Bolger JC; Fagan A; Byrne C; Hao Y; Qin L; McIlroy M; Xu J; Hill AD; Gaora PÓ; Young LS
Cancer Res; 2012 Jan; 72(1):220-9. PubMed ID: 22072566
[TBL] [Abstract][Full Text] [Related]
4. LGI1 and LGI4 bind to ADAM22, ADAM23 and ADAM11.
Sagane K; Ishihama Y; Sugimoto H
Int J Biol Sci; 2008; 4(6):387-96. PubMed ID: 18974846
[TBL] [Abstract][Full Text] [Related]
5. ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis.
Charmsaz S; Doherty B; Cocchiglia S; Varešlija D; Marino A; Cosgrove N; Marques R; Priedigkeit N; Purcell S; Bane F; Bolger J; Byrne C; O'Halloran PJ; Brett F; Sheehan K; Brennan K; Hopkins AM; Keelan S; Jagust P; Madden S; Martinelli C; Battaglini M; Oesterreich S; Lee AV; Ciofani G; Hill ADK; Young LS
BMC Med; 2020 Nov; 18(1):349. PubMed ID: 33208158
[TBL] [Abstract][Full Text] [Related]
6. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
7. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
8. LGI1-associated epilepsy through altered ADAM23-dependent neuronal morphology.
Owuor K; Harel NY; Englot DJ; Hisama F; Blumenfeld H; Strittmatter SM
Mol Cell Neurosci; 2009 Dec; 42(4):448-57. PubMed ID: 19796686
[TBL] [Abstract][Full Text] [Related]
9. The NFkappaB pathway and endocrine-resistant breast cancer.
Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
[TBL] [Abstract][Full Text] [Related]
10. Interaction of developmental transcription factor HOXC11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer [corrected].
McIlroy M; McCartan D; Early S; O Gaora P; Pennington S; Hill AD; Young LS
Cancer Res; 2010 Feb; 70(4):1585-94. PubMed ID: 20145129
[TBL] [Abstract][Full Text] [Related]
11. ADAM23 is a negative regulator of K
Lancaster E; Burnor E; Zhang J; Lancaster E
Neurosci Lett; 2019 Jun; 704():159-163. PubMed ID: 30965109
[TBL] [Abstract][Full Text] [Related]
12. The role of estrogen receptor-β in breast cancer.
Murphy LC; Leygue E
Semin Reprod Med; 2012 Jan; 30(1):5-13. PubMed ID: 22271289
[TBL] [Abstract][Full Text] [Related]
13. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
14. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
15. Sex hormone receptors in breast cancer.
D'Abreo N; Hindenburg AA
Vitam Horm; 2013; 93():99-133. PubMed ID: 23810004
[TBL] [Abstract][Full Text] [Related]
16. Biological characterization of ADAM22 variants reveals the importance of a disintegrin domain sequence in cell surface expression.
Sagane K; Sugimoto H; Akaike A
J Recept Signal Transduct Res; 2010 Apr; 30(2):72-7. PubMed ID: 20156119
[TBL] [Abstract][Full Text] [Related]
17. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors.
Ohkawa T; Fukata Y; Yamasaki M; Miyazaki T; Yokoi N; Takashima H; Watanabe M; Watanabe O; Fukata M
J Neurosci; 2013 Nov; 33(46):18161-74. PubMed ID: 24227725
[TBL] [Abstract][Full Text] [Related]
18. MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells.
Chen J; Miller EM; Gallo KA
Oncogene; 2010 Aug; 29(31):4399-411. PubMed ID: 20514022
[TBL] [Abstract][Full Text] [Related]
19. Cadherins and the mammary gland.
Knudsen KA; Wheelock MJ
J Cell Biochem; 2005 Jun; 95(3):488-96. PubMed ID: 15838893
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
